Nektar Therapeutics
NKTRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeNektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The $1.27B market capitalization puts NKTR squarely in small-cap range for its industry. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma.
Market Cap
$1.27B
Beta
1.27
P/E (TTM)
—
P/E (Fwd)
-3.61
EPS (TTM)
$-18.96
EPS (Fwd)
$-10.30
ROE
-35.8%
ROA
-12.5%
Cash
$684.3M
Total Debt
$135.9M
Free CF
-$134.8M
52W Change
-38.1%
Annual Financials
Cash vs Debt
Where NKTR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NKTR finished 46.85% below its 150-day moving average ($68.94) and 43.73% below its 200-day moving average ($65.12). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NKTR overbought or oversold?
At the October 20, 2026 close, NKTR's RSI(14) was 13.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $684.3M in cash and $135.9M in debt, NKTR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$134.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -35.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $92.1M (2022) to $55.2M (2025), a 40% decline worth watching.
With cash comfortably exceeding debt, NKTR has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NKTR.